OBJECTIVE(S): The poor prognosis associated with ovarian cancer is due to the lack of overt early symptoms and the absence of reliable diagnostic screening methods. Since many tumors overexpress anti-apoptotic proteins, the purpose of this study was to determine whether elevated levels of the anti-apoptotic protein Bcl-2 were present in urine from patients with ovarian cancer. METHODS: Bcl-2 was assayed by ELISA in urine samples from two cohorts consisting of a total of 77 healthy women, 161 women with benign gynecologic disease and 150 women with ovarian cancer, 13 with early and 137 with late stage disease, respectively. Wherever possible, parallel serum samples were measured for CA125 levels by ELISA. RESULTS: Urinary levels of Bcl-2 from healthy individuals or women with benign disease averaged 0.59 ng/ml+/-0.61 and 1.12 ng/ml+/-0.79, respectively. In contrast, urinary levels of Bcl-2 averaged 2.60 ng/ml+/-2.23 and 3.58 ng/ml+/-1.55 from women with early (N=13) and late (N=137) stage ovarian cancer. Further, urinary levels of Bcl-2 were elevated in ovarian cancer patients regardless of tumor grade, stage, size, histologic subtype, creatinine levels or patient age, but appeared to complement CA125 measurements. CONCLUSION(S): Levels of Bcl-2 are elevated in the urine of patients with ovarian cancer and may be of diagnostic and/or prognostic clinical importance. Further studies of urinary Bcl-2 as a biomarker for ovarian cancer alone or in combination with other markers are warranted.
OBJECTIVE(S): The poor prognosis associated with ovarian cancer is due to the lack of overt early symptoms and the absence of reliable diagnostic screening methods. Since many tumors overexpress anti-apoptotic proteins, the purpose of this study was to determine whether elevated levels of the anti-apoptotic protein Bcl-2 were present in urine from patients with ovarian cancer. METHODS:Bcl-2 was assayed by ELISA in urine samples from two cohorts consisting of a total of 77 healthy women, 161 women with benign gynecologic disease and 150 women with ovarian cancer, 13 with early and 137 with late stage disease, respectively. Wherever possible, parallel serum samples were measured for CA125 levels by ELISA. RESULTS: Urinary levels of Bcl-2 from healthy individuals or women with benign disease averaged 0.59 ng/ml+/-0.61 and 1.12 ng/ml+/-0.79, respectively. In contrast, urinary levels of Bcl-2 averaged 2.60 ng/ml+/-2.23 and 3.58 ng/ml+/-1.55 from women with early (N=13) and late (N=137) stage ovarian cancer. Further, urinary levels of Bcl-2 were elevated in ovarian cancerpatients regardless of tumor grade, stage, size, histologic subtype, creatinine levels or patient age, but appeared to complement CA125 measurements. CONCLUSION(S): Levels of Bcl-2 are elevated in the urine of patients with ovarian cancer and may be of diagnostic and/or prognostic clinical importance. Further studies of urinary Bcl-2 as a biomarker for ovarian cancer alone or in combination with other markers are warranted.
Authors: Ibrahim Khalifeh; Adnan R Munkarah; Fulvio Lonardo; John M Malone; Robert Morris; W Dwayne Lawrence; Rouba Ali-Fehmi Journal: Int J Gynecol Pathol Date: 2004-04 Impact factor: 2.762
Authors: Rebecca Sutphen; Yan Xu; George D Wilbanks; James Fiorica; Edward C Grendys; James P LaPolla; Hector Arango; Mitchell S Hoffman; Martin Martino; Katie Wakeley; David Griffin; Rafael W Blanco; Alan B Cantor; Yi-jin Xiao; Jeffrey P Krischer Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-07 Impact factor: 4.254
Authors: Edward R Sauter; Inna Chervoneva; Anastasia Diamandis; Javad M Khosravi; Samuel Litwin; Eleftherios P Diamandis Journal: Cancer Detect Prev Date: 2002
Authors: R A M Sagarra; L A L A Andrade; E Z Martinez; G A Pinto; K J Syrjänen; S F M Derchain Journal: Int J Gynecol Cancer Date: 2002 Nov-Dec Impact factor: 3.437
Authors: R P Woolas; F J Xu; I J Jacobs; Y H Yu; L Daly; A Berchuck; J T Soper; D L Clarke-Pearson; D H Oram; R C Bast Journal: J Natl Cancer Inst Date: 1993-11-03 Impact factor: 13.506
Authors: Ingegerd Hellstrom; Patrick J Heagerty; Elizabeth M Swisher; Pu Liu; Jade Jaffar; Kathy Agnew; Karl Erik Hellstrom Journal: Cancer Lett Date: 2010-04-08 Impact factor: 8.679
Authors: John B Liao; Yuen Yee Yip; Elizabeth M Swisher; Kathy Agnew; Karl Erik Hellstrom; Ingegerd Hellstrom Journal: Gynecol Oncol Date: 2015-04-09 Impact factor: 5.482